{"id":"https://openalex.org/W2249059299","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3525","title":"Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab in combination with escalating doses of oral cediranib for patients with advanced malignancies","display_name":"Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab in combination with escalating doses of oral cediranib for patients with advanced malignancies","alternate_titles":[],"publication_year":2009,"publication_date":"2009-05-20","ids":{"openalex":"https://openalex.org/W2249059299","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3525","mag":"2249059299"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2009.27.15_suppl.3525","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3525","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.3525","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2249059299"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5110288702","display_name":"Darren W. Davis","orcid":"https://orcid.org/0000-0001-6407-9430","observed_orcids":["https://orcid.org/0000-0001-6407-9430"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. W. Davis","raw_affiliation_strings":["ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002308810","display_name":"W. Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"W. Liu","raw_affiliation_strings":["ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"R. Kurzrock","raw_affiliation_strings":["ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005436649","display_name":"Aung Naing","orcid":"https://orcid.org/0000-0002-4803-8513","observed_orcids":["https://orcid.org/0000-0002-4803-8513"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"A. Naing","raw_affiliation_strings":["ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036211173","display_name":"Jennifer J. Wheler","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Wheler","raw_affiliation_strings":["ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022324869","display_name":"Linda W. Ricks","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"L. W. Ricks","raw_affiliation_strings":["ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080736692","display_name":"S. Percy Ivy","orcid":"https://orcid.org/0000-0001-7747-072X","observed_orcids":["https://orcid.org/0000-0001-7747-072X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"S. Ivy","raw_affiliation_strings":["ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026095888","display_name":"David S. Hong","orcid":"https://orcid.org/0000-0001-8721-1609","observed_orcids":["https://orcid.org/0000-0001-8721-1609"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"D. Hong","raw_affiliation_strings":["ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ApoCell, Inc., Houston, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Department of Investigational Cancer Therapeutics; IDB/CTEP/DCTD/NCI, Rockville, MD","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1343551460"],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"27","issue":"15_suppl","first_page":"3525","last_page":"3525"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10336","display_name":"Cancer Cells and Metastasis","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/circulating-tumor-cells","display_name":"circulating tumor cells","score":0.996999979019165},{"id":"https://openalex.org/keywords/circulating-endothelial-cells","display_name":"circulating endothelial cells","score":0.9879999756813049},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9779999852180481},{"id":"https://openalex.org/keywords/cediranib","display_name":"cediranib","score":1.0},{"id":"https://openalex.org/keywords/vegfr-inhibition","display_name":"VEGFR inhibition","score":0.777999997138977},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.9380000233650208},{"id":"https://openalex.org/keywords/vegfr2-phosphorylation","display_name":"VEGFR2 phosphorylation","score":0.878000020980835},{"id":"https://openalex.org/keywords/erk1-2-phosphorylation","display_name":"ERK1/2 phosphorylation","score":0.9269999861717224},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.8629999756813049},{"id":"https://openalex.org/keywords/endoglin","display_name":"CD105","score":0.7039999961853027},{"id":"https://openalex.org/keywords/cd31","display_name":"CD31","score":0.9959999918937683},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.8700000047683716},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5609999895095825},{"id":"https://openalex.org/keywords/treatment-response-prediction","display_name":"treatment response prediction","score":0.6110000014305115},{"id":"https://openalex.org/keywords/laser-scanning-cytometry","display_name":"laser scanning cytometry","score":0.8360000252723694},{"id":"https://openalex.org/keywords/cellsearch","display_name":"CellSearch","score":0.9570000171661377}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8967628479003906},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6871073842048645},{"id":"https://openalex.org/C61238886","wikidata":"https://www.wikidata.org/wiki/Q5121689","display_name":"Circulating tumor cell","level":4,"score":0.6741881370544434},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6058750748634338},{"id":"https://openalex.org/C6061869","wikidata":"https://www.wikidata.org/wiki/Q18250377","display_name":"Endoglin","level":4,"score":0.5979277491569519},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.5599034428596497},{"id":"https://openalex.org/C2778939058","wikidata":"https://www.wikidata.org/wiki/Q4046167","display_name":"CD31","level":3,"score":0.5495256185531616},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48377344012260437},{"id":"https://openalex.org/C553184892","wikidata":"https://www.wikidata.org/wiki/Q1141429","display_name":"Flow cytometry","level":2,"score":0.4820860028266907},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.477047860622406},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.39795464277267456},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.39745503664016724},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3954079747200012},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3693113327026367},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.35799306631088257},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3007347583770752},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.27481240034103394},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2671760320663452},{"id":"https://openalex.org/C10205521","wikidata":"https://www.wikidata.org/wiki/Q4035578","display_name":"CD34","level":3,"score":0.17279404401779175},{"id":"https://openalex.org/C2779013556","wikidata":"https://www.wikidata.org/wiki/Q181876","display_name":"Metastasis","level":3,"score":0.0991862416267395},{"id":"https://openalex.org/C28328180","wikidata":"https://www.wikidata.org/wiki/Q48196","display_name":"Stem cell","level":2,"score":0.08748790621757507},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2009.27.15_suppl.3525","doi":"https://doi.org/10.1200/jco.2009.27.15_suppl.3525","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2009.27.15_suppl.3525","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":1,"referenced_works":["https://openalex.org/W2106353572"],"related_works":["https://openalex.org/W2229870830","https://openalex.org/W2121731125","https://openalex.org/W2051701164","https://openalex.org/W1973232671","https://openalex.org/W2253030614","https://openalex.org/W1977246023","https://openalex.org/W2278052588","https://openalex.org/W2138636755","https://openalex.org/W4760471","https://openalex.org/W2575566375"],"abstract_inverted_index":{"3525":[0],"Background:":[1],"Rare":[2],"circulating":[3],"tumor":[4],"cells":[5,9,155],"(CTCs)":[6],"and":[7,30,39,45,56,69,73,80,92,96,114,163,174,213,224,254,287,296],"endothelial":[8,278],"(CECs)":[10],"offer":[11],"a":[12,131,185,210,234,241],"feasible":[13],"approach":[14],"for":[15,157],"studying":[16],"the":[17,25,36,150,180,221,238,247,261,272],"pharmacodynamic":[18],"effects":[19,26],"of":[20,27,35,66,229,252,256,282],"investigational":[21],"agents.":[22],"We":[23],"investigated":[24],"bevacizumab":[28],"(B)":[29],"cediranib":[31],"(C)":[32],"on":[33],"inhibition":[34,167,236],"VEGFR":[37],"pathway":[38],"correlated":[40,106],"these":[41],"changes":[42,198],"with":[43,107,271],"dose":[44,64],"clinical":[46],"response.":[47],"Methods:":[48],"Peripheral":[49],"blood":[50],"was":[51,87,141],"obtained":[52],"at":[53,57,143,171,293],"baseline,":[54],"24hrs":[55],"C2D26\u201330":[58],"post-treatment":[59],"from":[60],"patients":[61],"(n=14)":[62],"undergoing":[63],"escalation":[65],"intravenous":[67],"B":[68,286],"oral":[70],"C.":[71],"CTCs":[72,217,232],"CECs":[74,125,183,259,268,283],"(CD31+":[75],"or":[76,111],"CD105+)":[77],"were":[78,105,199],"isolated":[79],"immunofluorescently":[81],"stained.":[82],"Laser":[83],"scanning":[84],"cytometry":[85],"(LSC)":[86],"used":[88],"to":[89,147,190,301,312],"quantify":[90],"phosphorylated":[91],"total-VEGFR2":[93],"(pVEGFR2/VEGFR2),":[94],"pERK/ERK,":[95],"apoptosis":[97,140,257],"in":[98,102,139,149,168,192,201,216,220,231,237,244,246,258,266],"each":[99,103],"phenotype.":[100],"Changes":[101],"biomarker":[104],"partial":[108],"response":[109],"(PR)":[110],"stable":[112],"disease":[113],"progression":[115],">":[116],"2":[117],"months,":[118],"evaluated":[119],"using":[120],"RECIST.":[121],"Results:":[122],"Overall,":[123],"immature":[124],"(CD105+)":[126],"enumerated":[127],"by":[128,204],"CellSearch\u2122":[129],"revealed":[130,160,184,209,233],"dose-dependent":[132,186],"significant":[133,165,187,197,309],"decrease":[134],"(p=0.0001).":[135],"A":[136],"3-fold":[137],"induction":[138,255],"observed":[142,200],"24":[144],"hrs":[145],"compared":[146],"baseline":[148],"CD105+":[151,267],"CECs.":[152],"Mature":[153],"CD31+":[154],"assessed":[156],"VEGFR2":[158],"activity":[159],"an":[161],"83%":[162],"1.9%":[164],"(p=0.019)":[166],"pVEGFR2":[169,230,253],"expression":[170,194,245],"low":[172],"(B;3mg/kg)":[173],"high":[175],"(B;5mg/kg)":[176],"doses,":[177,295],"respectively.":[178,227],"In":[179],"non-responders,":[181],"mature":[182],"increase":[188,215,243,265],"(-6.8%":[189],"63%;p=0.031)":[191],"pERK/ERK":[193],"levels.":[195],"No":[196,308],"CTC":[202,207],"enumeration":[203,208],"CellSearch\u2122.":[205],"LSC-mediated":[206],"4.77":[211],"%":[212],"2.33%":[214],"following":[218],"treatment":[219],"non-":[222],"responders":[223],"responder":[225,239],"(p=0.809),":[226],"Analysis":[228],"58%":[235],"versus":[240],"163%":[242],"non-responders":[248],"(p=0.63).":[249],"Conclusions:":[250],"Inhibition":[251],"confirmed":[260],"target":[262],"therapy.":[263],"An":[264],"is":[269],"consistent":[270],"hypothesis":[273],"that":[274,285],"anti-angiogenic":[275],"efficacy":[276],"induces":[277],"cell":[279],"shedding.":[280],"Assessment":[281],"indicates":[284],"C":[288],"are":[289],"more":[290],"biologically":[291],"active":[292],"lower":[294],"resistance":[297],"may":[298],"be":[299],"attributed":[300],"ERK":[302],"activity.":[303],"Support:":[304],"UO1":[305],"CA062461":[306],"(RK)":[307],"financial":[310],"relationships":[311],"disclose.":[313]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2249059299","counts_by_year":[],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2016-06-24T00:00:00"}
